Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microwave ablation + adebrelimab ± apatinib in advanced solid tumors
NCT06537505Phase 2Not yet recruiting
- Sponsor
- Beidahuang Group General Hospital
- Start
- Aug 2024
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, randomised, open-label trial of adebrelimab in non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) (2 arms), sponsored by Beidahuang Group General Hospital. Primary endpoint: Objective Response Rate at 24 months. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06537505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06537505.